HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY
Investment Highlights
• Novel immuno-oncology B-cell peptide vaccine technology
• Outstanding scientific provenance from leading U.S. and European universities
• Drug is safe and well tolerated
• Sound cash position
• Robust intellectual property portfolio & long patent life including checkpoint inhibitor combinations
• Manufacturing straightforward with low cost of goods
• Published in leading peer review journals
To view Presentation please download PDF attached:
Download this document
